Celgene and Evotec have put capital into Exscientia as the Dundee-founded automated drug discovery services provider added Roche to its roster of development partners.
Exscientia, a UK-based drug discovery technology spinout of University of Dundee, received $26m yesterday in a series B round backed by pharmaceutical developer Celgene and drug developer Evotec. The deal also includes funding from venture firm GT Healthcare Capital Partners. Commercialisation firm Frontier IP, an existing investor in Exscientia, owns a 3.3% stake in the…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
